Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Manchester Asthma and Allergy Study - primary prevention of asthma and allergy by allergen avoidance in high risk infants
ISRCTN ISRCTN63558189
ClinicalTrials.gov identifier
Public title Manchester Asthma and Allergy Study - primary prevention of asthma and allergy by allergen avoidance in high risk infants
Scientific title Manchester Asthma and Allergy Study - primary prevention of asthma and allergy by allergen avoidance in high risk infants: a randomised controlled trial
Acronym MAAS
Serial number at source N/A
Study hypothesis Living in a low allergen environment reduces the risk of primary sensitisation and the development of atopic disease in children at high risk
Lay summary
Ethics approval South Manchester Research Ethics Committee gave approval on the 24th March 1994 (ref: WJP/CMI/ERP/94/032)
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Asthma
Participants - inclusion criteria High risk children (both parents atopic) of either sex born at Wythenshawe Hospital Manchester and Stepping Hill Hospital Stockport between January 1996 and April 1998.
Participants - exclusion criteria Premature birth less than 32 weeks gestation.
Anticipated start date 01/09/1995
Anticipated end date 01/06/2019
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 300
Interventions House dust mite allergen avoidance versus no intervention.
Primary outcome measure(s) 1. Asthma at age 5, 8, 11, and 14 years
2. Sensitisation at age 1, 3, 5, 8, 11 and 14 years
Secondary outcome measure(s) Wheeze and eczema at age 1, 3, 5, 8, 11 and 14 years.
Sources of funding 1. Asthma UK (UK)
2. Moulton Charitable Trust (UK)
Trial website
Publications 1. 2001 results in http://www.ncbi.nlm.nih.gov/pubmed/11476835
2. 2004 environmental control results in http://www.ncbi.nlm.nih.gov/pubmed/15142868
Contact name Prof  Adnan  Custovic
  Address North West Lung Research Centre
Wythenshawe Hospital
Southmoor Road
  City/town Manchester
  Zip/Postcode M23 9LT
  Country United Kingdom
  Tel +44 (0)161 291 2494
  Fax +44 (0)161 291 5057
  Email adnan.custovic@manchester.ac.uk
Sponsor Wythenshawe Hospital (UK)
  Address c/o Andrew Maines
R&D Directorate
ERC Building
Wythenshawe Hospital
Southmoor Road
  City/town Manchester
  Zip/Postcode M23 9LT
  Country United Kingdom
  Tel +44 (0)161 291 5775
  Fax +44 (0)161 291 5771
  Email andrew.maines@manchester.ac.uk
Date applied 26/09/2005
Last edited 09/02/2009
Date ISRCTN assigned 19/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central